Vaccine developer Arbovax, Inc. closed its Series A round with a total investment of $1.43 million, led by Piedmont Angel Networks (PAN) with additional investment from the Research Development Foundation, Carson City, Nevada and
Mario Family Partners. Arbovax, is developing technology designed to help produce vaccines against insect-borne viruses.
Malcolm Thomas, president and CEO of Arbovax, Inc. has been a CED member since 2005. He participated in the Angel Retreat at CED's 25th Anniversary Venture Conference.